Faraz S. Ahmad, Iben M. Ricket, Bradley G. Hammill, Lisa Eskenazi, Holly R. Robertson, Lesley H. Curtis, Cecilia D. Dobi, Saket Girotra, Kevin Haynes, Jorge R. Kizer, Sunil Kripalani, Mathew T. Roe, Christianne L. Roumie, Russ Waitman, W. Schuyler Jones, and Mark G. Weiner
This study outlines the recruitment process for the ADAPTABLE study (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness), a pragmatic, randomized, open-label clinical trial that tested the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. Investigators identified 650,000 potential eligible patients and recruited them at community sites, linking together data from the 40 sites in the Patient-Centered Outcomes Research Network to understand eligibility. The study was ultimately able to successfully enroll 15,076 patients in a significantly lower-cost way than most trials.